Manchester Biotech Imperagen Raises £5M to Advance Quantum-AI Enzyme Engineering Platform
Key Insights
Imperagen (search) secured £5 million in seed funding led by PXN Ventures (search) to expand its quantum physics and AI-driven enzyme (search) engineering platform, bringing total capital raised to £8.5 million.
The company's technology combines quantum-based simulations with AI models and automated robotics to predict and optimize enzyme (search) mutations, moving beyond traditional trial-and-error methods.
Commercial applications have demonstrated significant productivity gains, with enzyme (search) improvements of 677 times and 572 times achieved after five optimization cycles in partnership with a Fortune 500 personal care company.
Manchester-based biotech startup Imperagen (search) has raised £5 million in seed funding to advance its quantum physics and artificial intelligence-powered enzyme (search) engineering platform. The round was led by PXN Ventures (search), with participation from existing investors IQ Capital (search) and Northern Gritstone (search), bringing the company's total capital raised to £8.5 million.
The funding will enable Imperagen (search) to expand its research and development platform, scale laboratory operations, grow its AI team, and support commercial expansion across pharmaceuticals, life sciences, personal care, and industrial biotechnology sectors over the next 18 months.
Quantum-AI Approach to Enzyme Engineering
Imperagen (search) has developed a system that combines quantum physics simulations, AI, and automated robotics in a continuous feedback loop to accelerate enzyme (search) engineering. The process begins by using quantum-based modeling to simulate millions of possible enzyme mutations and predict their behavior. These predictions train AI models built around specific engineering problems rather than broader general-purpose systems.
Automated robotics systems then test the most promising candidates in the laboratory and feed results back into the model, allowing the system to improve over time. Each round of testing helps narrow the search and improve future predictions, with the platform continuously learning from physical lab results and refining recommendations with each cycle.
This approach is designed to move beyond traditional trial-and-error methods by using quantum modeling to improve prediction accuracy. The company noted that newer AI-based methods can struggle to perform reliably outside controlled environments, while their quantum-enhanced system addresses challenges faced by current AI enzyme (search) engineering efforts that struggle to transition from lab results to industrial production.
Commercial Validation and Applications
The platform has already demonstrated significant results in commercial projects. In collaboration with a Fortune 500 personal care company developing a new product line, Imperagen (search)'s system improved the productivity of two enzymes by 677 times and 572 times, respectively, after five rounds of optimization. Commercial projects have shown enzyme (search) productivity gains of more than 500 times after repeated optimization cycles.
Enzymes serve as biological catalysts across industries ranging from pharmaceutical manufacturing and personal care products to sustainable chemicals and industrial biotechnology. They help reduce waste, lower energy use, and cut production costs, making them increasingly important for developing greener manufacturing processes and creating cleaner, safer, and more sustainable products.
Leadership and Strategic Direction
The company announced the appointment of Guy Levy-Yurista as CEO, who previously led and scaled technology and life sciences companies in both Europe and the United States. Levy-Yurista joins as Imperagen (search) moves into its next phase of commercialization.
"What I see right now is that the companies that will make a radical difference in this emerging AI-driven future are all AI-native, lean on real world data, have genuine impact and are fundamentally deep tech," Levy-Yurista stated. "Imperagen (search) has each of those characteristics, combining them with outstanding people, phenomenal technology and the undeniable swagger you only get from Manchester."
Market Position and Future Outlook
The enzyme (search) engineering market is experiencing growing investment, with several companies developing AI-driven solutions. Competitors like Zymergen (search) (now part of Ginkgo Bioworks) and Codexis have demonstrated the potential of AI in biological engineering, but Imperagen (search)'s focus on quantum simulation could provide a competitive advantage.
Under Levy-Yurista's leadership, the company is preparing for expansion with plans to hire AI specialists, advance research and development, upgrade laboratory facilities, and build a market entry strategy over the next two years. The strategy centers on using engineered enzymes to achieve commercial success while delivering environmental benefits across multiple industrial applications.